Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Aticaprant Supratherapeutic Dose · 1 trial · 1 indication
Change from baseline in QTc at each time point will be reported.
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence 1 | EXPERIMENTAL | Healthy participants will receive single oral dose of Aticaprant (Dose 1) (Treatment A) in Treatment Period 1, followed by Moxifloxacin (Dose 2) (Treatment D) in Treatment Period 2, followed by Aticaprant (Dose 3) (Treatment B) in Treatment Period 3 and then placebo (Treatment C) in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period. |
| Treatment Sequence 2 | EXPERIMENTAL | Healthy participants will receive single oral dose of Treatment B in Treatment Period 1, followed by Treatment A in Treatment Period 2, followed by Treatment C in Treatment Period 3 and then Treatment D in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period. |
| Treatment Sequence 3 | EXPERIMENTAL | Healthy participants will receive single oral dose of Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3 and then Treatment A in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7-15 days between each treatment period. |
| Treatment Sequence 4 | EXPERIMENTAL | Healthy participants will receive single oral dose of Treatment D in Treatment Period 1, followed by Treatment C in Treatment Period 2, followed by Treatment A in Treatment Period 3 and then Treatment B in Treatment Period 4, on Day 1 of each treatment period. There will be a wash-out period up to 7 to 15 days between each treatment period. |
| Name | Type | Description |
|---|---|---|
| Aticaprant Supratherapeutic Dose | DRUG | Aticaprant supratherapeutic dose capsule will be administered orally. |
| Aticaprant Therapeutic Dose | DRUG | Aticaprant therapeutic dose capsule will be administered orally. |
| Placebo | DRUG | Placebo will be administered orally. |
| Moxifloxacin | DRUG | Moxifloxacin capsule will be administered orally. |
Inclusion Criteria: * Healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and admission to the study center on Day -1 of the first treatment period. Minor abnormalities in ECG, which are not considered to be of clini...
Aticaprant Supratherapeutic Dose is an investigational small molecule being studied in healthy adult participants. It is being evaluated in a clinical trial to assess its effects on cardiac repolarization, specifically through a thorough QT study. The drug is in Phase 1 clinical development and is not approved for any medical use.
Aticaprant Supratherapeutic Dose is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The company is conducting clinical research on this investigational small molecule in healthy volunteers.
Aticaprant Supratherapeutic Dose is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a completed Phase 1 trial that enrolled 60 healthy adult participants.
Aticaprant Supratherapeutic Dose is associated with one completed clinical trial, NCT05387759, titled "A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants." This Phase 1 study was conducted in Belgium and enrolled 60 healthy adults aged 18 years and older.
Yes, Aticaprant Supratherapeutic Dose is also known as JNJ-67953964. The clinical trial NCT05387759 uses this alternative name in its title, referring to the same investigational small molecule being developed by Johnson & Johnson.